Endo Pharmaceuticals
Also known as: Endo | Endo Global Aesthetics Limited | ENDO GLOBAL AESTHETICS LTD | ENDO OPERATIONS | ENDO PHARM | Endo Pharmaceuticals | Endo Pharmaceuticals (formerly Valera/Indevus Pharmaceuticals) | EndoPharmceuticals | Endo Pharmceuticals | ENDO PHARMS | ENDO PHARMS INC | Endo (v1) | Endo (v2) | ENDO VENTURES | ENDO VENTURES LTD
Highest phase reached
Phase 4
Timeline
1990s
- Jul 1, 1997
Endo Pharmaceuticals— Founded
2000s
- Jan 1, 2006
RxKinetix— Acquired
- Jan 1, 2009
Indevus Pharmaceuticals— Acquired
2010s
- Jan 1, 2010
Penwest Pharmaceuticals Co.— Acquired
- Jan 1, 2011
American Medical Systems— Acquired
- Jan 1, 2013
Boca Pharmacal— Acquired
- Jan 1, 2013
NuPathe Inc.— Acquired
- Jan 1, 2014
Auxillium— Acquired
- Jan 1, 2014
DAVA Pharmaceuticals— Acquired
- Jan 1, 2014
Somar— Acquired
- Feb 26, 2014
Paladin Labs— Acquired
- May 18, 2015
Par Pharmaceuticals— Acquired
- Apr 15, 2016
sodium phenylbutyrate— Marketing Organization
- Apr 26, 2018
Somerset Therapeutics LLC— Acquired
- Apr 26, 2018
Wintac Limited— Acquired
2020s
- Oct 19, 2020
Biospecifics Technologies Corp.— Acquired
- Mar 1, 2025
Mallinckrodt (2013)— Acquired By
Drugs by trial phase (131 distinct, 316 trials)
Phase 4 (13 own, 6 via acquisition)
Phase 3 (8 own, 27 via acquisition)
Phase 2 (5 own, 28 via acquisition)
Indications
Approved for
Studied for
- Acquired Immunodeficiency Syndrome
- Acromegaly
- Acute Pain
- Adenocarcinoma
- Ankle Injuries
- Anorexia
- Atrophy
- Back Pain
- Bone Diseases, Metabolic
- Breakthrough Pain
- Bursitis
- Cachexia
- Carcinoid Tumor
- Carcinoma
- Carcinoma in Situ
- Carcinoma, Transitional Cell
- Cardiovascular Diseases
- Carpal Tunnel Syndrome
- Cellulite
- Chlamydia Infections
- Chronic Disease
- Chronic Pain
- Communicable Diseases
- Complex Regional Pain Syndromes
- Constriction, Pathologic
- Contracture
- Dermatitis
- Dermatitis, Atopic
- Diabetic Neuropathies
- Dupuytren Contracture
- Eczema
- Edema
- Eunuchism
- Gonorrhea
- Headache
- Head and Neck Neoplasms
- Herpes Genitalis
- HIV Infections
- HIV Wasting Syndrome
- Hypertrophy
- Hypogonadism
- Infections
- Low Back Pain
- Lung Diseases
- Lung Diseases, Obstructive
- Malignant Carcinoid Syndrome
- Migraine Disorders
- Mucositis
- Multiple Sclerosis
- Muscular Atrophy
- Neuralgia
- Neuralgia, Postherpetic
- Osteoarthritis
- Osteoarthritis, Knee
- Osteoporosis
- Penile Induration
- Peripheral Nervous System Diseases
- Postoperative Pain
- Premature Birth
- Premature Ejaculation
- Premenstrual Syndrome
- Prostatic Neoplasms
- Puberty, Precocious
- Pulmonary Disease, Chronic Obstructive
- Recurrence
- Reflex Sympathetic Dystrophy
- Sarcopenia
- Schizophrenia
- Sclerosis
- Serotonin Syndrome
- Spinal Stenosis
- Sprains and Strains
- Stomatitis
- Stuttering
- Syndrome
- Tendinopathy
- Wasting Syndrome
- Weight Gain
Marketed drugs (101)
Subsidiaries (14 direct, 23 total across the full acquisition tree)
- American Medical Systems
- Auxillium
- Biospecifics Technologies Corp.
- Boca Pharmacal
- DAVA Pharmaceuticals
- Indevus Pharmaceuticals
- NuPathe Inc.
- Paladin Labs
- Par Pharmaceuticals
- Penwest Pharmaceuticals Co.
- RxKinetix
- Somar
- Somerset Therapeutics LLC
- Wintac Limited
- Actient L2
- Allon Therapeutics L2
- Anchen Pharmaceuticals, Inc L2
- Ethics Bio Lab L2
- JHP Pharmaceuticals LLC L2
- Labopharm L2
- Moderna Therapeutics L2
- VIRexx L2
- Slate Pharmaceuticals L3
Recent trials (50)
- NCT06649539CollaboratorPhase 4Oct 11, 2024
- NCT06169319Lead sponsorPhase 2Dec 31, 2023
- NCT06169319Study directorPhase 2Dec 31, 2023
- NCT06151197Lead sponsorPhase 3Nov 30, 2023
- NCT06151197Study directorPhase 3Nov 30, 2023
- NCT05777031CollaboratorPhase 4Oct 2, 2023
- NCT05419505Study directorPhase 2Jun 15, 2022
- NCT05419505Lead sponsorPhase 2Jun 15, 2022
- NCT05254457Lead sponsorPhase 3Feb 14, 2022
- NCT05254457Study directorPhase 3Feb 14, 2022
- NCT05152173Study directorPhase 2Nov 29, 2021
- NCT05152173Lead sponsorPhase 2Nov 29, 2021
- NCT04874870CollaboratorPhase 3Jul 12, 2021
- NCT05026216CollaboratorPhase 4Mar 29, 2021
- NCT04786106CollaboratorPhase 4Dec 30, 2020
Details
- Founded
- Malvern, PA, US Jul 1, 1997
- Last known activity
- Oct 11, 2024
Designations held
- Priority review